| Company/Division name | Garonit Pharmaceutical |
| Parent company | Garonit Pharmaceutical |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 1000 |
| Year reshoring announced: | 2026 |
| Year reshoring implemented or to be implemented: | 2031 |
| Capital investment ($): | 200 |
| City reshored to: | Flanders |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | active pharmaceutical ingredient (API) |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Under-utilized capacity |
